News

Enlarge image

ResearchDenmark

Trial success for Lundbeck

10.04.2013 - In a thorough comparison, Lundbeck's new antidepressant Brintellix shone brightly: On a system for rating depression patients performed better.

Danish H. Lundbeck A/S reported on positive results for the REVIVE study, a double-blind randomised study of Brintellix (vortioxetine) in adults with major depressive disorder (MDD) who changed antidepressant treatment after an inadequate response to SSRI or SNRI treatment. In this study, the objective was to compare the efficacy and tolerability of flexible dose treatment with Brintellix (10-20mg/day) versus Servier's agomelatine (25-50mg/day) in this challenging MDD patient population. "Patients with inadequate response to current SSRI or SNRI therapies represent a large proportion of patients suffering from major depression. Only a few years ago, the landmark STAR*D study1 confirmed a significant unmet medical need, as only half of patients responded to their first-line treatment, which was an SSRI," said Executive Vice President Anders Gersel Pedersen, Head of Research & Development at Lundbeck. The US-American FDA accepted an NDA from Lundbeck and its partner Takeda on Brintellix last December. 

Brintellix is under investigation as a multimodal antidepressant thought to work through a combination of two complementary mechanisms of action: receptor activity modulation and reuptake inhibition. In vivo non-clinical studies have demonstrated that Brintellix modulates neuronal firing and neurotransmitter release in multiple systems, resulting in enhanced levels of serotonin, noradrenaline, dopamine, acetylcholine and histamine in specific areas of the brain. The multimodal activity profile of Brintellix is different from the profile of currently anti-depressive medicines.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/trial-success-for-lundbeck.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)52.22 USD54.5%
  • CLINIGEN GRP (UK)675.00 GBP35.0%

FLOP

  • MOLOGEN (D)1.75 EUR-30.8%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)57.15 CHF-17.9%

TOP

  • KARO BIO (S)29.80 SEK1810.3%
  • NICOX (F)11.20 EUR471.4%
  • SAREUM HOLDINGS (UK)0.62 GBP169.6%

FLOP

  • BB BIOTECH (D)45.00 EUR-83.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 26.07.2016